Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Rapid Test and Treat with Dovato in Newly Diagnosed HIV-1
NCT03945981Phase 3Completed
- Sponsor
- ViiV Healthcare
- Start
- Jul 2019
- Primary completion
- Apr 2020
- Modality
- Orthosteric Ligands, Metabolically Activated Prodrugs
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of dolutegravir + lamivudine in human immunodeficiency virus type 1 infection (HIV-1), sponsored by ViiV Healthcare. Primary endpoint: Percentage of Participants With Plasma HIV-1 RNA <50 Copies/mL at Week 24. Started Jul 2019; status: completed.
02
Drugs
dolutegravir + lamivudine
03
Conditions
human immunodeficiency virus type 1 infection (HIV-1)
Beyond the preview
Go deeper on NCT03945981.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03945981.